PF-06952229, a selective TGF-?-R1 inhibitor: preclinical development and a first-in-human, phase I, dose-escalation study in advanced solid tumors.
PF-06952229, a selective TGF-?-R1 inhibitor: preclinical development and a first-in-human, phase I, dose-escalation study in advanced solid tumors. ESMO Open. 2024 Sep; 9(9):103653.